

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-HP 3808	SERIAL NO.: 09/632,928
	APPLICANT: Watson-Straughan et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: August 4, 2000	GROUP: 1621

## U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE ISSUED	NAME	CLASS	SUB- CLASS	FILING DATE
SA	5,010,175	4-23-91	Rutter et al.			5-2-88
	5,508,432	4-16-96	Sugg et al.			6-8-94
	5,534,530	7-9-96	Frehel et al.			4-13-94
	5,646,140	7-8-97	Sugg et al.			1-4-94 (PCT)
	5,656,648	8-12-97	Bolgegrain et al.			6-7-95
	5,731,340	3-24-98	Bras et al.			8-16-95
	5,739,129	4-14-98	Aquino et al.			4-12-95 (PCT)
	5,795,887	8-18-98	Aquino et al.			4-13-95 (PCT)
	5,859,007	1-12-99	Aquino et al.			4-13-95 (PCT)
	5,889,182	3-30-99	Dezube et al.			10-12-95 (PCT)
SA	Ser. No. 09/027,108		Dooley et al.			2-20-98

## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	PUB. DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATIO (YES/NO)
SA   SA	WO 91/19735	26 Dec 1991	PCT			
	WO 98/34113	6 Aug 1998	PCT			
	WO 99/21571	6 May 1999	PCT			Abstract only

LHB 8/12/02

Form 1449

Ser. No. 09/632,928

Page 2

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

91		Catania and Lipton, "α-Melanocyte-Stimulating Hormone peptides in Host responses," <u>Ann. N.Y. Acad. Sci.</u> , 680:412-23 (1993).
		Catania et al., "The Neuropeptide α-MSH has Specific Receptors on Neutrophils and reduces Chemotaxis In Vitro," <u>Peptides</u> , 17:675-79 (1996).
		Dorr et al., "Evaluation of melatonin-IT, a Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study," <u>Life Sciences</u> , 58:1777-84 (1996).
		Fan et al., "Role of melanocortinergeric neurons in feeding and the agouti obesity syndrome," <u>Nature</u> , 385:165-68 (1997).
		Hotamisligil and Spiegelman, "Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link," <u>Diabetes</u> , 43:1271-78 (1994).
		Hotamisligil et al., "Increased Adipose Tissue Expression of Tumor Necrosis Factor-α in Human Obesity and Insulin Resistance," <u>J. Clin. Invest.</u> , 95:2409-15 (1995).
		Hotamisligil et al., "Reduced Tyrosine Kinase Activity of the Insulin Receptor in Obesity-Diabetes," <u>J. Clin. Invest.</u> , 94:1543-49 (1994).
		Huszar et al., "Targeted Disruption of the Melanocortin 4 Receptor Results in Obesity in Mice," <u>Cell</u> , 88:131-41 (1997).
		Kuby, "Immunology," 3 <sup>rd</sup> ed., Chapter 13 (W.H. Freeman & Co.; N.Y. 1997).
		Ollmann et al., "Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein," <u>Science</u> , 278:135-37 (1997).
		Ostresh, "Solid-Phase Synthesis of Trisubstituted Bicyclic Guanidines via Cyclization of Reduced N-Acylated Dipeptides," <u>J. Org. Chem.</u> , 63:8622-23 (1998).
		Platzer et al., "Up-regulation of monocytic IL-10 by tumor necrosis factor-α and camp elevating drugs," <u>International Immunology</u> , 7:517-23 (1995).
		Star et al., "Evidence of autocrine modulation of macrophage nitric oxide synthase by α-melanocyte-stimulating hormone," <u>Proc. Natl. Acad. Sci. USA</u> , 92:8016-20 (1995).
		Jeffrey B. Tatro, "Receptor Biology of the Melanocortins, a family of Neuroimmunomodulatory Peptides," <u>Neuroimmunomodulation</u> , 3:259-84 (1997).
51		Xia et al., "Expression of melanocortin 1 receptor in periaqueductal gray matter," <u>NeuroReport</u> , 6:2193-96 (1995).

8/12/02